New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Chrys Pulle

Dr Chrys Pulle

Practical Strategies for Behaviour Management in Dementia

A/Prof Michael Woodward AM

A/Prof Michael Woodward AM

The New Pneumococcal Vaccination for Older Adults – What You Need to Know

Prof Rodney Baber AM

Prof Rodney Baber AM

Adolescent Contraception – Common Myths

Dr Jo-Ann See

Dr Jo-Ann See

Acne Practical Cases – Trunk, Skin of Colour

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970